Clinical Trial

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Name: To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) — clinical trial record (NCT07116473)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).

Trial Details

NCT Number	NCT07116473
Lead Sponsor	Eidos Therapeutics, a BridgeBio company
Conditions	Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related +2 more
Enrollment	250 participants
Start Date	2026-11
Primary Completion	2037-11 (estimated)
Study Completion	2037-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-11